The widespread adoption of imaging techniques such as positron emission tomography (PET), using radiotracers targeting the prostate-specific membrane antigen (PSMA), has significantly improved the early detection of recurrent prostate cancer (PCa). This evidence concerns the gene FOLH1 and posterior cortical atrophy.